CRNX News

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

CRWV CLASS ACTION: Did CoreWeave, Inc. Mislead Investors? BFA Law Notifies Investors to Contact the Firm by March 13 about the Filed Securities Class Action

ViroMissile Appoints Michael G. Wood as Chief Business Officer

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia